DC13 — Lipid-mediator class-switching drugs

DC13 — Lipid-mediator class-switching drugs
DC13
Status: Closed
Supervisor
Professor Oliver Werz
Host Institution
Friedrich Schiller University Jena
City
Jena
Country
Germany

About this Project

This project will develop compounds that shift lipid-mediator production away from pro-inflammatory mediators and towards specialised pro-resolving mediators. It will define the underlying enzyme pathways and investigate whether class-switching compounds act synergistically with omega-3 fatty acids and marine-derived bioactives.

Your profile and what you'll gain

Skills required

Background in pharmaceutical sciences, pharmacology, biochemistry, chemistry or molecular medicine; experience with cell-based assays or analytical techniques is advantageous.

Skills acquired

Lipid-mediator biosynthesis, lipoxygenase biology, primary leukocyte assays, compound screening and optimisation, LC-MS/MS lipidomics, structure-activity analysis, computational lipid-network modelling and evaluation of omega-3-derived bioactives.

Eligibility Criteria

Before applying, candidates should ensure they meet the following eligibility criteria:

  • have a MSc degree in Life Sciences or obtain a MSc degree by October 2026
  • have completed a research internship with relevant expertise
  • have obtained high grades during his/her studies
  • be fluent in English (some countries may also require language certifications – this will be communicated to applicants following shortlisting)
  • applicant must not have resided in the country of the recruiting organisation for more than 12 months preceding the recruitment date. 
Supervisor
Professor Oliver Werz
• Closed
Host Institution
Friedrich Schiller University Jena
City
Jena
Country
Germany

Applications closed

Applications closed on 1 October 2026 and are now under review.

Share this project

15 doctoral projects

Find the project that fits you

  • DC1
    • Closed

    Cellular mechanisms of inflammation resolution in rheumatoid arthritis

    Supervisor: Professor Gerhard Krönke
    Institution: Charité – Universitätsmedizin Berlin
  • DC2
    • Closed

    Pro-resolving mechanisms in rheumatoid arthritis-associated cardiovascular disease

    Supervisor: Professor Catherine Godson
    Institution: University College Dublin
  • DC3
    • Closed

    Why does inflammation resolve in some forms of arthritis but persist in others?

    Supervisor: Dr Marc Dubourdeau
    Institution: AMBIOTIS
  • DC4
    • Closed

    Cardiac-cell metabolism in inflammatory arthritis

    Supervisor: Professor Mauro Perretti
    Institution: Queen Mary University of London
  • DC5
    • Closed

    Specialised pro-resolving mediators in cardiometabolic disease: human population studies

    Supervisor: Dr Marleen van Greevenbroek
    Institution: Maastricht University
  • DC6
    • Closed

    Macrophage-fibroblast mechanisms restoring joint immune homeostasis

    Supervisor: Professor Mariola Kurowska-Stolarska
    Institution: University of Glasgow
  • DC7
    • Closed

    MCTR3 signalling in synovial inflammation and tissue repair

    Supervisor: Professor Jesmond Dalli
    Institution: Queen Mary University of London
  • DC8
    • Closed

    Role of canonical–atypical chemokine receptor axis in resolution of inflammation

    Supervisor: Professor Martine Smit
    Institution: Vrije Universiteit Amsterdam
  • DC9
    • Closed

    Redox control of inflammatory fibroblast priming

    Supervisor: Professor Markus Hoffmann
    Institution: University Hospital Schleswig-Holstein
  • DC10
    • Closed

    Macrophage-derived specialised pro-resolving mediators in hypertension and cardiovascular damage

    Supervisor: Professor Ana Maria Briones
    Institution: Universidad Autónoma de Madrid
  • DC11
    • Closed

    Computational identification of therapeutic checkpoints and resolution-promoting agents

    Supervisor: Professor Olaf Wolkenhauer
    Institution: University of Rostock
  • DC12
    • Closed

    Small-molecule promoters of inflammation resolution

    Supervisor: Professor Trond V. Hansen
    Institution: University of Oslo
  • DC14
    • Closed

    Resomelagon in rheumatoid arthritis and cardiovascular comorbidities

    Supervisor: Professor Mauro Perretti
    Institution: Queen Mary University of London
  • DC15
    • Closed

    Specialised pro-resolving mediators as regulators of haematopoiesis in rheumatoid arthritis and cardiovascular disease

    Supervisor: Professor Jesmond Dalli
    Institution: Queen Mary University of London